Form 8-K - Current report:
SEC Accession No. 0001104659-21-136929
Filing Date
2021-11-10
Accepted
2021-11-10 16:06:12
Documents
16
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2132541d1_8k.htm   iXBRL 8-K 29979
2 EXHIBIT 99.1 tm2132541d1_ex99-1.htm EX-99.1 59318
7 GRAPHIC image_001.jpg GRAPHIC 5744
8 GRAPHIC image_002.jpg GRAPHIC 15593
  Complete submission text file 0001104659-21-136929.txt   348003

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cycc-20211110.xsd EX-101.SCH 3427
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cycc-20211110_def.xml EX-101.DEF 27312
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cycc-20211110_lab.xml EX-101.LAB 36925
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cycc-20211110_pre.xml EX-101.PRE 25937
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2132541d1_8k_htm.xml XML 5201
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 211396540
SIC: 2834 Pharmaceutical Preparations